Wnt Signaling Pathway and Chronic Myelogenous Leukemia
As a type of cancer that starts in certain blood-forming cells of the bone marrow, chronic myeloid leukemia (CML) is caused by the formation of an abnormal gene called BCR-ABL1. The targeted medicine TKI for BCR-ABL1 has great effect on treating CML: however, TKI is not able to completely remove the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-02-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0899.htm |
| Summary: | As a type of cancer that starts in certain blood-forming cells of the bone marrow, chronic myeloid leukemia (CML) is caused by the formation of an abnormal gene called BCR-ABL1. The targeted medicine TKI for BCR-ABL1 has great effect on treating CML: however, TKI is not able to completely remove the leukemia stem cells (LSCs) in CML patients, which will lead to drug resistance and leukemia relapse. With the application of Wnt signaling pathway in regulating stem cell function, many studies have found that it also plays an important role in treating CML. In this paper, we reviewed the impact of Wnt signaling pathway on CML therapy. |
|---|---|
| ISSN: | 1000-8578 1000-8578 |